Admission Date:  [**2160-5-8**]              Discharge Date:   [**2160-5-13**]  Date of Birth:  [**2115-11-4**]             Sex:   F  Service: SURGERY  Allergies: Patient recorded as having No Known Allergies to Drugs  Attending:[**First Name3 (LF) 5547**] Chief Complaint: synovial sarcoma of right groin  Major Surgical or Invasive Procedure: Radical resection of synovial sarcoma of right groin with en bloc resection of right common femoral artery.
Split-thickness skin graft of 0.014-inch, 10 x 2 inches.
She underwent preoperative radiation therapy to a dose of 5000 cGy that was completed approximately 5-6 weeks ago.
She presents at this time for definitive surgical resection of this sarcoma.
Preoperative consultation with Dr. [**First Name (STitle) **] of plastic surgery was obtained for a planned rotational flap coverage of the soft tissue defect.
The risks and benefits of the procedure were discussed in detail with the patient with the aid of a translator and the consent was signed.
Family History: Significant for diabetes in her mom  Physical Exam: afebrile, VSS NAD, A and O x3 HEENT: NC, NT Chest: CTAB CV: RRR, -MRG Abd: soft/NT/ND, +BS RLE: confluent mass of the right groin   Pertinent Results: [**2160-5-12**] 06:40AM BLOOD Hct-32.3* [**2160-5-11**] 08:10AM BLOOD Hct-32.3* [**2160-5-10**] 06:50AM BLOOD WBC-7.3 RBC-3.51* Hgb-9.9* Hct-28.1* MCV-80* MCH-28.1 MCHC-35.1* RDW-13.1 Plt Ct-190 [**2160-5-9**] 04:57AM BLOOD WBC-9.9 RBC-3.66* Hgb-10.0* Hct-29.4* MCV-80* MCH-27.3 MCHC-34.1 RDW-13.4 Plt Ct-224 [**2160-5-8**] 07:59PM BLOOD WBC-14.4* RBC-4.06* Hgb-11.0* Hct-33.3* MCV-82 MCH-27.0 MCHC-32.9 RDW-12.9 Plt Ct-281 [**2160-5-8**] 11:45AM BLOOD WBC-12.8* RBC-3.87* Hgb-10.7* Hct-31.0* MCV-80* MCH-27.7 MCHC-34.6 RDW-13.0 Plt Ct-283 [**2160-5-8**] 07:59PM BLOOD PT-11.5 PTT-26.4 INR(PT)-1.0 [**2160-5-11**] 09:30PM BLOOD Glucose-120* UreaN-11 Creat-0.6 Na-134 K-4.0 Cl-99 HCO3-25 AnGap-14 [**2160-5-10**] 06:50AM BLOOD Glucose-114* UreaN-7 Creat-0.5 Na-136 K-4.1 Cl-101 HCO3-27 AnGap-12 [**2160-5-9**] 04:57AM BLOOD Glucose-130* UreaN-11 Creat-0.5 Na-136 K-4.2 Cl-103 HCO3-25 AnGap-12 [**2160-5-8**] 07:59PM BLOOD Glucose-194* UreaN-10 Creat-0.6 Na-136 K-4.6 Cl-103 HCO3-20* AnGap-18  Brief Hospital Course: The patient tolerated the surgery well and was initially moved to the ICU overnight after her surgery for frequent pulse checks.
Neuro: The patient received IV PCA with dilaudid initially after the surgery with good effect and adequate pain control.
As her diet was advanced she was switched to oral oxycodone with good pain control.
She had [**Initials (NamePattern4) **] [**Last Name (NamePattern4) 55863**] palpable DP and PT pulse following surgery bilaterally.
The patient's intake and output were closely monitored, and IVF were adjusted when necessary.
It was removed on POD5 by plastic surgery and the skin graft looked healthy and was inplace.
This was dressed with xeroform and multiple fluffs.
She will receive VNA care for further dressing changes.
Prophylaxis:  The patient received subcutaneous heparin during this stay, and was encouraged to get up and ambulate as early as possible.
She will receive home VNA for dressing changes and JP care.
Medications on Admission: levothyroxine  Discharge Medications: 1.
Levothyroxine 50 mcg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Docusate Sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 times a day).
Aspirin 81 mg Tablet, Chewable Sig: One (1) Tablet, Chewable PO DAILY (Daily).
Oxycodone 5 mg Tablet Sig: 1-2 Tablets PO Q4H (every 4 hours) as needed.
Famotidine 20 mg Tablet Sig: One (1) Tablet PO BID (2 times a day).
Discharge Disposition: Home With Service  Facility: [**Location (un) 86**] VNA  Discharge Diagnosis: Synovial sarcoma of right groin, status post preoperative radiation therapy.
*Avoid driving or operating heavy machinery while taking pain medications.
* Please resume all regular home medications and take any new meds as ordered.
-Keep drain attached safely to body to prevent pulling  please continue dressings over your skin graft as instructed by the VNA nursing staff.
